BIAF news

The company will showcase its CyPath Lung test at the Lung Cancer Initiative of NC's event, emphasizing early detection for curative outcomes.

bioAffinity aims to improve lung cancer risk stratification at CHEST 2026 with its noninvasive sputum-based CyPath Lung test, led by Chief Medical Officer Dr. Gordon Downie. The company also plans to discuss investigative research for asthma and COPD.

bioAffinity Technologies received a notice of allowance for a Japanese patent covering its CyPath Lung test, expanding its intellectual property and protecting the noninvasive lung cancer diagnostic in the Asian market.

The company debuted its noninvasive lung cancer test at NAVREF 2026. This partnership expands federal access to the test and addresses a significant health burden within the veteran community.

bioAffinity Technologies will present data on its CyPath Lung diagnostic system at NAVREF, demonstrating benefits in clinical practice and for veteran populations. The conference highlights the company's efforts to address lung cancer among veterans and commercial potential with new partners.

The Hong Kong Intellectual Property Department granted a patent for CyPath Lung, reinforcing the company's intellectual property portfolio in Asia, a region accounting for nearly two-thirds of global lung cancer cases.

The company received confirmation from Nasdaq that it has regained compliance with the minimum bid price and rights and warrants rules, canceling the previously scheduled hearing. Maintaining its stock listing is critical for the biotech firm to focus on the commercialization of its CyPath Lung test…

CEO Maria Zannes will present a corporate update and meet with investors at the 28th Annual Global Investment Conference. This announcement details upcoming milestones for the CyPath Lung diagnostic test.

bioAffinity Technologies has entered into a nationwide distribution agreement with AvMEDICAL to market CyPath Lung to federal healthcare agencies, including the VA, thereby expanding commercial reach.

CyPath Lung test volume increased 216% year over year, boosting H1 2026 revenue to $835,000 and bolstering the company's commercial momentum. Bottom-line financials are currently unavailable.

bioAffinity Technologies released a clinical review outlining protocols for using CyPath Lung in pulmonary nodule evaluation, addressing the need for risk stratification in primary care, pulmonology, and oncology settings.

bioAffinity Technologies has partnered with Pictor to develop and commercialize diagnostic tests for asthma and COPD, creating a more comprehensive picture of lung inflammation. This collaboration increases laboratory throughput.

bioAffinity Technologies reported Q2 2026 CyPath Lung sales growth of over 200% to a new record driven by increased physician adoption and repeat utilization. The acceleration in test volume underscores a strong commercial trajectory for the company's non-invasive lung cancer diagnostics.

Unit sales for CyPath Lung increased nearly 300% in April 2026 versus the prior year. The company also announced a collaboration with Philips to enhance lung cancer screening for U.S. veterans.

bioAffinity Technologies entered into a placement agency agreement with WallachBeth Capital to sell up to $3.2 million in securities comprising common stock at $0.80 per share and pre-funded warrants at $0.793. The offering provides capital for the company through a registered direct offering under …

bioAffinity Technologies partnered with Philips and 4DMedical to host a July 21, 2026 webinar on lung health screening for U.S. veterans, featuring CyPath Lung testing and mobile CT imaging. The initiative aims to improve early detection and access to lung cancer diagnostics for at-risk veteran popu…

bioAffinity Technologies announced a June 16 webinar featuring physicians discussing real-world benefits of its noninvasive CyPath Lung test for early-stage lung cancer detection. The event highlights the test's clinical utility in reducing unnecessary invasive procedures and supporting cancer surve…

bioAffinity Technologies announced notification of patent allowance from Mexico's Institute of Industrial Property for methods using flow cytometry and antibodies to detect lung cancer. The patent strengthens the company's global IP portfolio for its CyPath Lung diagnostic platform across multiple j…